| INTRODUC TI ON
Annually, influenza virus infections account for an estimated 3-5 million cases globally, with 250 000-500 000 deaths. Administration to treat seasonal influenza. 4, 5 Oseltamivir is the most widely used due to ease of oral administration. Data from Australasia and South-East Asia showed that influenza A viruses from 1998 through 2002 were overall more susceptible to the NAIs, oseltamivir, and zanamivir, than influenza B viruses. 6 However, in 2008, oseltamivir resistance was reported at a frequency of 90% globally for seasonal influenza A(H1N1) viruses and was associated with histidine to tyrosine mutation at position 275 (H275Y, N1 numbering) of the NA. 7, 8 During the 2008 influenza season, oseltamivir-resistant influenza A(H1N1) viruses were also isolated from South African patients with influenza-like illness. These influenza A(H1N1) virus isolates (n = 49) had the H275Y substitution and were confirmed to be phenotypically resistant to inhibition by oseltamivir.
9
Neuraminidase inhibitor resistance associated with the H275Y mutation was reported at a frequency of 3% (169/5152) in influenza A(H1N1)pdm09 virus isolates received at the World Health Organization (WHO) collaborating centers (CCs) from various geographic regions, 2013-2014. 7, 10 Global NAI susceptibility surveillance data from WHO-CCs for 2013-2014 include less than 3%
African data.
10
Both oseltamivir and zanamivir are licenced in South Africa.
Zanamivir is available since the early 2000s and oseltamivir since
2006
. 11, 12 Zanamivir is approved for treatment of children aged 7 years and older, whereas oseltamivir can be given to individuals of all ages. 13, 14 Although generally thought not to be widely prescribed, limited reports are available on the use of NAIs in South Africa. Benefit of oseltamivir for both treatment of and prophylaxis against influenza-associated respiratory illness in South African infants with low birthweight was reported. 15 Influenza A(H1N1) pdm09 H275Y-resistant phenotype viruses were reported in 1 of 54 (2%) of patients following 5-day standard dose oseltamivir treatment.
16
We aimed to determine oseltamivir and zanamivir susceptibility of influenza A and B virus NAs, 2007-2013, South Africa, and to investigate amino acid polymorphisms in NA. Briefly, MDCK cells were seeded in shell vials and maintained with Dulbecco's modified Eagle's medium (DMEM, Lonza, Allendale, NJ, USA) containing 4.5 g/L glucose, with l-glutamine, 10% fetal bovine serum, 2 mmol/L l-glutamine, and antibiotics. After inoculation with 250 microliter clinical specimen for 2 hours on washed serum-free cell monolayers, the cultures were incubated with DMEM serum media at 37ºC and harvested 24-73 hours later. Culture supernatant fluids from influenza virus cultures were stored at −70°C. 22, 23 Influenza virus isolates (2007-2009) were subtyped serologically by hemagglutination inhibition (HAI) and subtype-specific antisera. [23] [24] [25] Influenza viruses were detected by qRT-PCR, and influenza A positives were subtyped using a qRT-PCR assay from Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA). 18, 20, 21, 26 From 2009 to 2013, influenza-positive specimens with qPCR with cycle threshold (C t ) values <30 were selected for virus isolation.
| ME THODS

| Surveillance programs
In addition, we selected specimens for influenza virus isolation at the beginning, middle, and end of the South African influenza season (typically May through September). 7 N1 numbering is used in manuscript.
| Phenotypic drug resistance assays
| Neuraminidase inhibitorsusceptible and neuraminidase inhibitor-resistant reference virus isolates
| The NA-STAR and NA-XTD chemiluminescent assay
The NA-STAR and NA-XTD chemiluminescent assays (Applied Biosystems, Foster City, CA, USA) were used to determine the susceptibility of NA from influenza A and B virus isolates to oseltamivir and zanamivir. Virus culture supernatant fluid aliquots were retrieved and pre-treated with 10% Triton X-100 solution to inactivate virus. 27 The NA inhibition assays were performed following the manufacturers' protocols as described. 
| Detection of drug resistance mutations and drift in influenza virus neuraminidase
The NA genes of influenza A and B strains from 2009 to 2013
were amplified and sequenced from original clinical specimens.
Briefly, the universal influenza A and B primers (uni12 and Buni11)
were used for complementary DNA (cDNA) preparation followed by nested PCR. 30, 31 Sequencing was performed using the BigDye (Table 2 ). 
| Neuraminidase inhibitor susceptibility of influenza A and B isolates
| Amino acid substitutions in NA genes of influenza viruses
| D ISCUSS I ON
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been detected during seasonal epidemics and has been replaced by A(H1N1)pdm09. 44 Influenza viruses (H1N1 and H1N1pdm09) carrying the H275Y mutation and associated with clinical resistance to oseltamivir displayed > 400-fold increase in IC 50 .
9,45
No seasonal influenza A(H1N1) NAs were sequenced in this study. However, in 2008 the H275Y substitution was reported in resistant strains from South Africa. Resistance to inhibition by oseltamivir was reported at frequencies of 0.2% (2/900 adults) to 1.1% (2/190 children) for influenza A(H3N2) from combined studies including clinical trials conducted in Japan. 47 Oseltamivir resistance was mostly associated with E119V
and R292K mutations. 47 In global surveillance, data from 2013 to 2014 H3N2-resistant phenotype isolates were reported at 0.3%.
10
We observed that most A(H3N2) isolates displayed low NA activity, and therefore, NA susceptibility to antivirals could not be assessed.
Our inability to obtain A(H3N2) isolates with high levels of NA activity could be related to changes in phenotypic characteristics of A(H3N2) viruses. 48, 49 During virus isolation, only immunofluorescence and hemagglutination assays were routinely used to detect virus growth, which may further account for low number of isolates subsequently identified with high NA levels.
Despite observed continued drift in B lineages in this study, these mutations were not associated with NAI resistance or reduced susceptibility. The influenza B/Memphis/20/96 strain carrying the R150K mutation associated with highly reduced resistance to both zanamivir and oseltamivir and used in this study as reference resistant strain was initially isolated from an immune-compromised patient in the United States following zanamivir treatment. 50, 51 Susceptibility to NAIs was determined for influenza virus isolates This study provides baseline data on influenza A and B viruses with oseltamivir-susceptible phenotypes in South Africa.
Guidelines for the prevention and treatment of influenza in South Africa are published electronically. 52 However, although oral oseltamivir and inhaled zanamivir are available in South Africa, they are not routinely prescribed. 14, 53 This is also observed for hospitalized patients enrolled through our pneumonia surveillance program in public hospitals (C. Cohen, unpublished data). Oseltamivir is prescribed more frequently by private healthcare practitioners, but no data are available on the extent of use in South Africa.
Given the very low frequency of resistance reported globally, the use of NAIs to treat patients at high risk of developing severe illness should be promoted.
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